Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.

Clavé, P;Acalovschi, M;Triantafillidis, J K;Uspensky, Y P;OBIS study investigators;et.al.
(2011) Alimentary Pharmacology and Therapeutics. Symposium Series — Vol. 34, n° 4, p. 432-442 (2011)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 546.88 KB
No access

Details

Authors
  • Clavé, P
    Author
  • Acalovschi, M
    Author
  • Triantafillidis, J K
    Author
  • Uspensky, Y P
    Author
  • OBIS study investigatorsUCLouvain
    Author
Show more
Abstract
Otilonium bromide (OB) is a spasmolytic agent that blocks L-Type Calcium channels in human colonic smooth muscle.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Clavé, P., Acalovschi, M., Triantafillidis, J. K., Uspensky, Y. P., Kalayci, C., Shee, V., Tack, J., & OBIS study investigators. (2011). Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics. Symposium Series, 34(4), 432-442. https://doi.org/10.1111/j.1365-2036.2011.04730.x (Original work published 2011)